vs
Side-by-side financial comparison of Marygold Companies, Inc. (MGLD) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.
Marygold Companies, Inc. is the larger business by last-quarter revenue ($7.6M vs $7.0M, roughly 1.1× Relay Therapeutics, Inc.).
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.
MGLD vs RLAY — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.6M | $7.0M |
| Net Profit | $-576.0K | — |
| Gross Margin | 74.0% | — |
| Operating Margin | -8.3% | — |
| Net Margin | -7.5% | — |
| Revenue YoY | -4.5% | — |
| Net Profit YoY | 67.0% | — |
| EPS (diluted) | $-0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.6M | $7.0M | ||
| Q3 25 | $7.0M | $0 | ||
| Q2 25 | $7.2M | — | ||
| Q1 25 | $7.0M | $7.7M | ||
| Q4 24 | $8.0M | $0 | ||
| Q3 24 | $7.9M | $0 | ||
| Q2 24 | $8.3M | $0 | ||
| Q1 24 | $7.9M | $10.0M |
| Q4 25 | $-576.0K | — | ||
| Q3 25 | $-356.0K | $-74.1M | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-1.0M | $-77.1M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-1.6M | $-88.1M | ||
| Q2 24 | $-1.9M | $-92.2M | ||
| Q1 24 | $-529.0K | $-81.4M |
| Q4 25 | 74.0% | — | ||
| Q3 25 | 77.0% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 75.0% | — | ||
| Q4 24 | 74.1% | — | ||
| Q3 24 | 73.1% | — | ||
| Q2 24 | 72.5% | — | ||
| Q1 24 | 70.5% | — |
| Q4 25 | -8.3% | — | ||
| Q3 25 | -18.2% | — | ||
| Q2 25 | -16.5% | — | ||
| Q1 25 | -21.4% | -1105.2% | ||
| Q4 24 | -22.8% | — | ||
| Q3 24 | -27.4% | — | ||
| Q2 24 | -33.3% | — | ||
| Q1 24 | -18.7% | -903.0% |
| Q4 25 | -7.5% | — | ||
| Q3 25 | -5.1% | — | ||
| Q2 25 | -20.4% | — | ||
| Q1 25 | -14.4% | -1003.6% | ||
| Q4 24 | -21.8% | — | ||
| Q3 24 | -20.1% | — | ||
| Q2 24 | -22.5% | — | ||
| Q1 24 | -6.7% | -813.3% |
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $-0.01 | $-0.43 | ||
| Q2 25 | $-0.04 | — | ||
| Q1 25 | $-0.02 | $-0.46 | ||
| Q4 24 | $-0.04 | — | ||
| Q3 24 | $-0.04 | $-0.63 | ||
| Q2 24 | $-0.05 | $-0.69 | ||
| Q1 24 | $-0.01 | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.6M | $84.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $22.7M | $567.1M |
| Total Assets | $27.8M | $621.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $84.0M | ||
| Q3 25 | $12.5M | $91.6M | ||
| Q2 25 | $12.8M | — | ||
| Q1 25 | $15.6M | $93.5M | ||
| Q4 24 | $14.9M | $124.3M | ||
| Q3 24 | $17.5M | $152.4M | ||
| Q2 24 | $15.0M | $134.1M | ||
| Q1 24 | $16.1M | $152.9M |
| Q4 25 | $22.7M | $567.1M | ||
| Q3 25 | $22.9M | $607.7M | ||
| Q2 25 | $23.0M | — | ||
| Q1 25 | $24.3M | $721.1M | ||
| Q4 24 | $23.4M | $777.8M | ||
| Q3 24 | $25.5M | $838.9M | ||
| Q2 24 | $26.6M | $681.7M | ||
| Q1 24 | $28.4M | $745.8M |
| Q4 25 | $27.8M | $621.3M | ||
| Q3 25 | $28.4M | $670.0M | ||
| Q2 25 | $30.4M | — | ||
| Q1 25 | $33.5M | $799.4M | ||
| Q4 24 | $33.0M | $871.3M | ||
| Q3 24 | $35.9M | $930.1M | ||
| Q2 24 | $32.9M | $772.5M | ||
| Q1 24 | $33.7M | $841.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-908.0K | $-235.5M |
| Free Cash FlowOCF − Capex | — | $-235.9M |
| FCF MarginFCF / Revenue | — | -3370.0% |
| Capex IntensityCapex / Revenue | 0.0% | 5.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-622.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-908.0K | $-235.5M | ||
| Q3 25 | $-533.0K | $-62.1M | ||
| Q2 25 | $-3.3M | — | ||
| Q1 25 | $-1.2M | $-73.2M | ||
| Q4 24 | $-770.0K | $-249.1M | ||
| Q3 24 | $-893.0K | $-75.1M | ||
| Q2 24 | $-1.9M | $-65.8M | ||
| Q1 24 | $-658.0K | $-50.3M |
| Q4 25 | — | $-235.9M | ||
| Q3 25 | $-562.0K | $-62.1M | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | — | $-73.6M | ||
| Q4 24 | $-776.0K | $-251.1M | ||
| Q3 24 | $-940.0K | $-75.3M | ||
| Q2 24 | $-2.0M | $-65.8M | ||
| Q1 24 | — | $-52.1M |
| Q4 25 | — | -3370.0% | ||
| Q3 25 | -8.1% | — | ||
| Q2 25 | -46.8% | — | ||
| Q1 25 | — | -958.4% | ||
| Q4 24 | -9.7% | — | ||
| Q3 24 | -11.9% | — | ||
| Q2 24 | -23.8% | — | ||
| Q1 24 | — | -520.7% |
| Q4 25 | 0.0% | 5.9% | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.0% | 5.0% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.0% | 17.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
RLAY
Segment breakdown not available.
